Stay updated on CNTO 1959 Efficacy & Safety in Psoriasis: Clinical Trial
Sign up to get notified when there's something new on the CNTO 1959 Efficacy & Safety in Psoriasis: Clinical Trial page.

Latest updates to the CNTO 1959 Efficacy & Safety in Psoriasis: Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe ClinicalTrials.gov record for a Phase 3 guselkumab study of moderate-to-severe plaque psoriasis is now available, with study design, participant criteria, locations, outcomes, and posted results information.SummaryDifference70%

- Check14 days agoChange DetectedThe ClinicalTrials.gov footer now displays revision v3.8.0 instead of v3.7.2, while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check21 days agoChange DetectedA site-wide NIH banner announces updates and explains that NIH content may use “Super Intelligence” instead of “Artificial Intelligence” during a terminology transition.SummaryDifference1%

- Check28 days agoChange DetectedThe ClinicalTrials.gov footer now displays revision v3.7.2 instead of v3.7.1.SummaryDifference0.2%

- Check35 days agoChange DetectedThe site footer revision changes from v3.7.0 to v3.7.1, while the page remains a 403 Forbidden error.SummaryDifference0.2%

- Check56 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study details, with the header and footer visible. This indicates an access restriction or server issue preventing loading the study record.SummaryDifference20%

Stay in the know with updates to CNTO 1959 Efficacy & Safety in Psoriasis: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CNTO 1959 Efficacy & Safety in Psoriasis: Clinical Trial page.